+44 (0)203 011 5574 info@orthocg.com
Xtant Medical Announces Appointment of New Senior Sales Leaders

Xtant Medical Announces Appointment of New Senior Sales Leaders

BELGRADE, MT, Feb. 12, 2019 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the recent additions of five senior sales executives: Dana Lyons, Vice President of US Sales, Jamey Rottman, Regional Vice President, Mid Atlantic, Chris Cochran, Regional Vice President, South East, John Eekhof, Regional Vice President, North East, and Luke Armand, Regional Vice President, West. These additions, along with the appointment of Kevin Brandt, as Chief Commercial Officer, in July 2018, bring to the Company over 150 years of combined commercial experience and relationships in the spine industry.

In announcing the team, Kevin Brandt stated, “We are excited to welcome these dedicated and proven sales leaders to our team who will bring strong spine experience and have proven track records in this industry. Appointing these sales leaders demonstrates our commitment to competing in the spine market and leveraging the strength of our full product portfolio. These leaders all have an extended product and therapy knowledge, as well as deep relationships in the commercial spine market, which will provide great value to our customers and shareholders.”

Dana Lyons, Vice President of US Sales

Dana is well known in the medical device industry with 29 years of experience. He has served in various capacities at Biomet, Stryker, and Zimmer Spine, where he was instrumental in the growth of each organization. Most recently, Dana served as Vice President of Sales and Marketing for Amedica where he was able to expand the customer base, improve on the depth and breadth of the sales team, and successfully launch a new modular pedicle screw system to the market.

Jamey Rottman, RVP Sales, Mid-Atlantic Region

Jamey has over 25 years of experience in the spine industry, having worked for Spine Tech, Zimmer, Zimmer Biomet, and most recently Amedica. Jamey has held roles in marketing, sales training, professional education, and market development at the senior leadership level. Jamey has strong knowledge of the spine industry in both hardware and biologics.

Chris Cochran, RVP Sales, South East Region

Chris has over 25 years’ experience in sales and in spine. His skill set includes sales and marketing leadership as well as leading an independent medical device distributorship. Chris recently worked with Amedica as an area vice president where he was instrumental in increasing revenue both organically and following a company acquisition. He has also held leadership roles at Spineart USA, Life Spine, Tissue Banks International and Regeneration Technologies, Inc.

John Eekhof, RVP Sales, North East Region

John has over 25 years’ experience in the spine industry with executive leadership roles in sales and marketing. Most recently, John was a key leader in the international spinal and biologics business at Stryker Spine, with roles in product marketing and marketing communications. Prior to Stryker Spine, John was at Medtronic in various commercial spine leadership roles.

Luke Armand, RVP Sales, West Region

Luke brings over 18 years of combined experience in sales, marketing, product development and sales team development and management. Combined with his experience at Abbott Spine, LDR Spine, and RTI Surgical, he was most recently the regional sales director for North America at Curasan. Luke has a proven record of developing and implementing revenue driving initiatives.

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

Cautionary Note Regarding Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘will,” ‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ “continue,” “future,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the expectation that the new senior sales leaders will add great value to our customers and shareholders. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; its ability to increase revenue, remain competitive and innovate and develop new products; the effect of management changes and ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products, ability to obtain and maintain regulatory approvals; government regulations; product liability claims and other litigation to which the Company may be subject; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt and comply with debt covenants; the ability to raise additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC) on April 2, 2018 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed with the SEC on November 14, 2018. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

COMPANY CONTACT
Kathie Lenzen, Chief Financial Officer
406.388.0480
klenzen@xtantmedical.com

SOURCE: Xtant Medical Holdings, Inc. 14th Feb 2019

joimax® Announces New Distribution Partners in Brazil and Japan

joimax® Announces New Distribution Partners in Brazil and Japan

Expands International Market Presence as Part of Growth Strategy

KARLSRUHE, Germany–(BUSINESS WIRE)–joimax®, the Germany-based market leader of technologies and training methods for full-endoscopic minimally-invasive spinal surgery, is pleased to announce it has expanded its international market presence with new distribution partners in Brazil and Japan.

In Brazil, joimax® is partnering with the privately-owned CT Group, which offers more than 20 years experience in the medical technology market. CT Group delivers a unique strategy and approach in the Brazilian market, focusing on the spine segment. The group is composed of 5affiliated companies that provide innovative and high standard medical devices and equipment throughout the country.

“We are very happy to represent joimax® and its complete endoscopic product portfolio in Brazil,” states Volnei Luiz Ortigara, Chairman of the Brazilian CT Group. “Together, we will ensure an outstanding market presence.”

Currently, there are 50 potential providers in Brazil who have been trained on the joimax® methods and will be able to start offering joimax® endoscopic procedures this spring.

In Japan, joimax® is partnering with United Biomech Japan, Inc., who will oversee distribution of the complete joimax® product line countrywide. The official market launch will take place at the 48th Annual Meeting of the Japanese Society for Spine Surgery and Related Research (JSSR), April 18 – 20, 2019 in Yokohama, Japan. The agreement coincides with the Japan-EU Free Trade Agreement (JEFTA) which came into effect February 1, 2019.

“This is the first time joimax® will be involved with the Japanese market,” states Wolfgang Ries, Founder and CEO of the joimax®Group. “We are excited to extend our global reach and offer superior medical products and training internationally.”

The presence in these two major markets is part of theoverall growth strategy for joimax®. further positioning the company as a leader in the spine industry.

About joimax®

Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and marketer of complete systems for full-endoscopic and minimally invasive spinal surgery. With the Endoscopic Surgical Systems TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® for facet and sacroiliac joint pain treatment and EndoLIF® and Percusys® for minimally-invasive endoscopically assisted stabilizations, established systems are provided, addressing a whole range of indications.

In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions under local or full anesthesia, via tissue and muscle-sparing corridors and through natural openings in the spinal canal, e.g. the intervertebral foramen, the so-called “Kambin triangle”.

Contacts

Press Contact Germany: joimax® GmbH
Sabine Jarosch
sabine.jarosch@joimax.com
0049 721 25514 0

Press Contact USA :
joimax® Inc.
Melissa Brumley
melissa.brumley@joimaxusa.com
001 949 859 3472

SOURCE: BusinessWire, Feb 9, 2019

Gramercy Extremity Orthopedics® Receives US Patent No. 10,206,725 for Variable Angle Locking Technology

Gramercy Extremity Orthopedics® Receives US Patent No. 10,206,725 for Variable Angle Locking Technology

Gramercy Extremity Orthopedics (GEO®) receives US Patent No. 10,206,725 Which Covers a Novel Approach for Variable Angle Locking Technology

RICHARDSON, TEXAS, UNITED STATES, February 6, 2019 /EINPresswire.com/ — Gramercy Extremity Orthopedics (GEO®) receives US Patent No. 10,206,725 which covers a novel approach for Variable Angle Locking Technology, adding to the intellectual property GEO has established in this area. This patent covers a unique design that allows a screw to be fixed at various angles and orientations using self-aligning washers within the plate hole. The washer holes line up with the screw to facilitate insertion and provide a large interface area with the screw threads, increasing the strength of the construct.

“The granting of our second US variable angle locking patent continues to enhance GEO’s ability to bring Orthopedic Implant solutions to surgeon and patient needs” says Michael P. Simpson, CEO and President of GEO. “This technology has the potential to improve the current variable angle locking technology in Orthopedics.”

GEO will be exhibiting at the ACFAS Scientific Conference, New Orleans, Feb 14th – 17th, 2019. Booth #301.

About Gramercy Extremity Orthopedics:

GEO was formed from the idea that there could exist a more cost effective, user-friendly way to supply Orthopedic Medical Implants in today’s healthcare environment. This is accomplished through the use of technology, a groundbreaking Point-of-Sale delivery system and GEO designed best in class sterilized single use orthopedic implants and instruments. GEO is the only solution that provides a significant opportunity to lower real operating costs by creating efficiencies and controls throughout the delivery and consumption of orthopedic implants.

GRAMERCY EXTREMITY ORTHOPEDICS and GEO are proprietary trademarks of Gramercy Extremity Orthopedics, LLC. All rights reserved.

www.gramercyortho.com

Michael Nugent
Gramercy Extremity Orthopedics
+18135285005
email us here
Visit us on social media:
Facebook
LinkedIn

SOURCE: Gramercy Extremity Orthopedics® 

Spine Surgery Robots Market to be Worth US$320 Million by 2026, Says TMR

Spine Surgery Robots Market to be Worth US$320 Million by 2026, Says TMR

ALBANY, New York, January 25, 2019 /PRNewswire/ —

Looking at the growth prospects and growth initiatives taken by the key players for developing, spine surgery robots are expected to drive demand in this market. The spine surgery robots market earned US$75 mn in 2017. The valuation is likely to increase to US$320 mn by the end of this forecast period in 2026. The market is estimated to expand at 17.5% CAGR between 2018 and 2026. Transparency Market Research presents all the above-mentioned figures in its recent report.

Considering the methods used in spine surgery robots, the demand for minimally invasive procedures is likely to boost and might dominate half of the spine surgery robots market. Increasing demand from the patients for minimally invasive surgeries and high accuracy and safety procedures are the key factors driving demand in this segment. Based on geography, North America is expected to lead the market due to high demand for spine surgery robots in the U.S. rise in aging population and increase of advanced technology in healthcare led to demand for spine surgery robots in this region.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55677

High Demand for Minimally Invasive Procedures to Drive Market Performance

The global spine surgery robots market is expected to grow at a significant rate due to rapid development in robotic surgical technology and increasing demand for minimally invasive surgeries. Moreover, government and private firms have increased funding for research and development in this market, which has further led the growth in this market.

The demand for spine surgery robots is high in developed economies due to the availability of advanced technologies used in the healthcare sector and efficient and skilled surgeons ready to perform related surgeries.  Adding it further, the presences of huge geriatric population, the higher purchasing power of hospitals, and increasing number of surgical procedures are few other factors driving growth in the global spine surgery robots market.

Request a Sample of Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=55677

Additional Maintenance Cost for Spine Surgery Robots Hampering Market Growth

However, on the other hand, limited numbers of skilled professionals or surgeons in developing economies and expensive procedures with spine surgery robots are expected to hinder growth in the global spine surgery robots market. In addition, there is an additional cost for maintain spine surgery robots and require an additional disposable income that will also hamper the market’s growth.  Nevertheless, the convenience provided through low-cost robotics systems and accessories is likely to create lucrative opportunities in both developed and developing regions.

Request For Discount On This Reporthttps://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=55677

The global spine surgery robots market is likely to be consolidated, as the key players namely Medtech (Zimmer-Biomet) and Mazor Robotics hold 80% of share. Mazor Robotics deal in proprietary technologies and have introduced a new guidance system for spine surgeries. Other players in the market are also experimenting in spine surgery guidance. For example, Intuitive Surgical Inc. with its da Vinci system has made efforts in changing expanding and experimenting with the system. Players are also involved with expanding their product portfolio and gain a higher share in the market. Moreover, the presence of navigation systems is available in the market from last two decades but currently, they have low market share. However, these technologies have shown clinical value and can gain more attention in the coming years.

Browse Press Releasehttps://www.transparencymarketresearch.com/pressrelease/spine-surgery-robots-market.htm

The information presented in this review is based on a TMR report, titled “Spine Surgery Robots Market (Application – Spinal Fusion, Minimally Invasive Procedures, Scoliosis, Osteoporotic Compression Fractures; Method – Minimally Invasive, Open Surgery; Product – Systems, Accessories and Consumables; End user – Hospitals, Ambulatory Surgical Centers) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018 – 2026.”

Popular Research Reports by TMR:

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Research Blog: https://theglobalhealthnews.com/

SOURCE Transparency Market Research, PR Newswire Jan 25, 2019

Integra LifeSciences Launches Integra® Titan™ Reverse Shoulder System-S

Integra LifeSciences Launches Integra® Titan™ Reverse Shoulder System-S

PLAINSBORO, N.J., Jan. 10, 2019 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the full market release of the Integra® Titan™ Reverse Shoulder System-S (RSS-S).  This launch includes a new glenoid baseplate design to expand the Integra® Titan™ Reverse Shoulder System.

The new glenoid baseplate was designed with advanced imaging analysis to improve fit and stability for patients of varying anatomy. In reverse shoulder arthroplasty, strong fixation in the patient’s bone is key for long-term success of the implant construct.  The new RSS-S baseplate was designed to achieve immediate fixation with an independent central screw, and the porous-coated central post allows the patient’s bone to grow onto the implant to further maximize the potential for long-term fixation.

“We designed the Titan Reverse Shoulder System-S to leverage the latest data on glenoid morphology in various patient populations, while streamlining the instrumentation to improve the flow of each case,” said Dr. Matthew Ramsey of the Rothman Institute and a design surgeon of the system. “The new system builds upon the established legacy of our diaphyseal-fit humeral stems, which allow me to treat my patients without cement in primary and revision surgeries.”

“The Titan Reverse Shoulder System is the foundation of our shoulder portfolio and a key growth driver in our Extremity Orthopedics franchise,” said Robert T. Davis, Jr., corporate vice president and president, Orthopedics and Tissue Technologies.  “The launch of RSS-S demonstrates our commitment to continuous innovation in the shoulder arthroplasty space with the goal of improving patient outcomes.”

The Titan Reverse Shoulder System-S was developed with the following industry thought leaders: Matthew Ramsey, MD; William Geissler, MD; Reza Omid, MD; Jean-Marc Glasson, MD; Phillip Duke, MB.BS, FRACS, FA(ORTH)A; and Mark Ross, MB.BS.FRACS, FA(ORTH)A.

About Integra
Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™.  For the latest news and information about Integra and its brands, please visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2017 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Investors
Sravan Emany
(609) 936-2488
sravan.emany@integralife.com

Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com

Media 
Laurene Isip
609-750-7984
laurene.isip@integralife.com

SOURCE: GlobeNewswire, Jan 10, 2019